NCT01740531View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 21, 2017

Study Completion Date

December 31, 2017

Conditions
Thalassemia Major
Interventions
BIOLOGICAL

S-303 Treated Red Blood Cells (RBCs)

BIOLOGICAL

Conventional, untreated Red Blood Cells

Trial Locations (3)

Unknown

Ospedale Regionale per le Microcitemie Azienda, Cagliari

University of Torino, Torino

Ege University, Izmir

Sponsors

Lead Sponsor

Cerus Corporation
All Listed Sponsors
lead

Cerus Corporation

INDUSTRY

NCT01740531 - Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion | Biotech Hunter | Biotech Hunter